Glenmark Pharmaceuticals (GLENMARK.NS) Financial Analysis & Valuation | Quarter Chart
Glenmark Pharmaceuticals (GLENMARK.NS)
GLENMARK.NSPrice: $23.73
Fair Value: 🔒
🔒score
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respirator... more
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and market... more
Description
Shares
| Market Cap | $6.70B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IN | CEO | Glenn Mario Saldanha |
| IPO Date | 2002-07-01 | CAGR | 0.18% |
| Employees | 14,989 | Website | www.glenmarkpharma.com |
| Div. Yield | 0.22% | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | 0.22% |
GLENMARK.NS chart loading...
Fundamentals
Technicals
| Enterprise Value | $574.33B | P/E Ratio | 63.25 |
| Forward P/E | 22.23 | PEG Ratio | 2.85 |
| P/S Ratio | 3.91 | P/B Ratio | 6.7 |
| P/CF Ratio | 22.64 | P/FCF Ratio | 27.49 |
| EPS | $0.39 | EPS Growth 1Y | -631.27% |
| EPS Growth 3Y | 20.82% | EPS Growth 5Y | 11.27% |
| Revenue Growth 1Y | 17.27% | Gross Margin | 0.52% |
| Operating Margin | 0.14% | Profit Margin | 0.06% |
| ROE | 0.12% | ROA | 0.06% |
| ROCE | 0.2% | Current Ratio | 1.65 |
| Quick Ratio | 1.17 | Cash Ratio | 0.38 |
| Debt/Equity | 0.13 | Interest Coverage | 10.14 |
| Altman Z Score | 5.61 | Piotroski Score | 6 |